Diabetic Kidney Disease Position Paper of the Macedonian Society of Nephrology, Dialysis, Transplantation and Artificial Organs (MSNDTAO), Macedonian Society of Cardiology (MSC), and Scientific Association of Endocrinologists and Diabetologists of Macedonia (SAEDM).

Publisher: Makedonska akademija na naukite i umetnostite Country of Publication: North Macedonia NLM ID: 101677081 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1857-8985 (Electronic) Linking ISSN: 18579345 NLM ISO Abbreviation: Pril (Makedon Akad Nauk Umet Odd Med Nauki) Subsets: MEDLINE

Original Publication: Skopje : Makedonska akademija na naukite i umetnostite, [2013]-

Diabetic Nephropathies*/therapy; Humans ; Cardiology/standards ; Consensus ; Endocrinologists/standards ; Endocrinology/standards ; Endocrinology/methods ; Hypoglycemic Agents/therapeutic use ; Kidney Failure, Chronic/therapy ; Nephrologists/standards ; Nephrology/standards ; Republic of North Macedonia ; Risk Factors ; Societies, Medical/standards

Diabetic kidney disease (DKD) is a significant and growing global health concern, affecting a substantial proportion of individuals with diabetes mellitus. This position paper of Scientific societies of endocrinologists, nephrologists and cardiologists has been consensually brought at a couple of mutual meetings, aiming to synthesize current knowledge on screening, diagnosis and staging of DKD, emphasizing the need for an early detection and intervention in order to prevent progression to end-stage renal disease (ESRD). The role of glycemic control, blood pressure management, lipid management and the use of reno and cardioprotective agents, including angiotensin-converting enzyme inhibitors, sodium-glucose co-transporter 2 inhibitors and non-steroidal mineralocorticisteroid receptor antagonist has been entirely considered. Furthermore, we highlight the importance of a multidisciplinary approach in the care of patients with DKD, integrating lifestyle modifications and patient education into the clinical practice. This paper advocates for the implementation of standardized screening protocols and the development of personalized treatment strategies to optimize patient outcomes. By addressing the complexities of DKD, we aim to provide a comprehensive framework for healthcare professionals to enhance the quality of care for individuals at risk of or living with this condition.
(© 2024 Goce Spasovski et al., published by Sciendo.)

Rodriguez-Gutierrez R, Gionfriddo MR, Ospina NS, et al. Shared decision making in endocrinology: present and future directions. Lancet Diabetes Endocrinol 2016; 4: 706–716.
Draznin B, Aroda VR, Bakris G, et al. American Diabetes Association Professional Practice Committee. 6. Glycemic targets: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022; 45(Suppl. 1): S83–S96.
Marx N, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes; Eur Heart J 2023; 00: 1–98.
McDonagh TA, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Eur Heart J 2023; 00: 1–13.
American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care. 2024; 47(Suppl 1): S219-S230. doi:10.2337/dc24-S011.
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022; 102(4S): S1–S123.
Упатство за практивување на медицина ба-зирана на докази за превенција, дијагноза и водење на преддијабете, дијабетес тип 2 во здравствени установи од областа на општа/ семејна медицина, Слижбен весник на РСМ, Стр. 28 - Бр. 170, 10.08.2023.
Алгоритам за рана дијагноза и следење на хронична бубрежна болест (ХББ) кај лица со тип 2 дијабетес (Т2Д); Подготвено од: Маке-донско здружение за нефрологија, трансплан-тација дијализа и вептачки органи, Научно здружение на ендокринилози и дијабетолози на Македонија, Македонско здружение за ме-дицинска биохемија и лабораториска меди-цина, Здружение на интернисти на РМ, Ма-кедонско здружение по кардиологија, јануари 2024, .
Levin A, Tonelli M, Bonventre J, et al., ISN Global Kidney Health Summit participants. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet. 2017;3 90: 1888–1917.
de Boer I.H. et al; Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) Kidney International (2022) 102, Issue 5, 974–989.
.Levey AS, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150: 604–12.
Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021; 385(19): 1737–1749.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3: 1–150.
Sadusky T, Hurst C. The patient voice in health care decision making: the perspective of people living with diabetes and CKD. Clin J Am Soc Nephrol. 2021; 16: 991–992.
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International 2020; 98: S1–S115.
de Boer IH, Bangalore S, Benetos A, et al. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care. 2017; 40(9): 1273–1284.
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021; 99(3S): S1–S87.
Wanner C, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014; 85: 1303–1309.
Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipo-protein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010; 160: 785–794.e10.
EMPA-KIDNEY Collaborative Group. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. Lancet Diabetes Endocrinol. 2024; 12(1): 39–50.
Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, Schmedt N, Koeneman L, Déruaz-Luyet A, Paik JM, Patorno E. Cardio-renal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study. Cardiovasc Diabetol. 2024 Feb 8; 23(1): 57.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15): 1436–1446.
Perkovic V, Jardine MJ, Neal B, et al., CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.N Engl J Med. 2019; 380: 2295–2306.
Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61: 2461–2498.
Gerstein HC, Colhoun HM, Dagenais GR, et al.; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394: 121–130.
Hernandez AF, Green JB, Janmohamed S, et al.; Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018; 392: 1519–1529.
Mann JFE, Fonseca V, Mosenzon O, et al. Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease. Circulation. 2018;1 38: 2908–2918.
Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375: 1834–1844.
Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis [published correction appears in Eur Heart J. 2022 May 21; 43(20): 1989.

Keywords: Diabetic kidney disease; angiotensin-converting enzyme inhibitors; lifestyle modifications; non-steroidal mineralocorticosteroid receptor antagonist; sodium-glucose co-transporter 2 inhibitors

0 (Hypoglycemic Agents)

Date Created: 20241212 Date Completed: 20241212 Latest Revision: 20250114

20250115

10.2478/prilozi-2024-0027

39667008